| scholarly article | Q13442814 |
| P2093 | author name string | Zhang D | |
| Patel S | |||
| Wright SD | |||
| Chao YS | |||
| Peterson L | |||
| Hernandez M | |||
| Detmers PA | |||
| Burton CA | |||
| Hassing H | |||
| Hermanowski-Vosatka A | |||
| Mundt S | |||
| Rosa R | |||
| Sparrow CP | |||
| Wang PR | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| simvastatin | Q670131 | ||
| P304 | page(s) | 115-121 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering | |
| P478 | volume | 21 |
| Q36402808 | 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice |
| Q27005638 | A novel therapeutic effect of statins on nephrogenic diabetes insipidus |
| Q36697677 | A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction |
| Q37727091 | A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation |
| Q35126780 | Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies |
| Q43955453 | Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. |
| Q34981331 | Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? |
| Q34644504 | Antiinflammatory and immunomodulatory properties of statins |
| Q45184189 | Assessment of the efficacy of different statins in murine collagen-induced arthritis |
| Q41533633 | Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity. |
| Q28212769 | Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime |
| Q34514032 | Atherosclerosis and inflammation |
| Q35556348 | Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins |
| Q53172507 | Atorvastatin Upregulates the Expression of miR-126 in Apolipoprotein E-knockout Mice with Carotid Atherosclerotic Plaque. |
| Q43942237 | Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes |
| Q33323649 | Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells. |
| Q40456181 | Atrial fibrillation and plasma troponin I elevation after cardiac surgery: relation to inflammation-associated parameters. |
| Q47182880 | C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss |
| Q35848866 | CD40 ligand: a novel target in the fight against cardiovascular disease |
| Q24306455 | Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE) |
| Q33933964 | Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability |
| Q40445455 | Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts |
| Q40139803 | Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice. |
| Q35222472 | Clostridium difficile: improving the prevention paradigm in healthcare settings |
| Q44439746 | Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease |
| Q44021015 | Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice |
| Q36401585 | Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention |
| Q36406951 | Differential metabolic actions of specific statins: clinical and therapeutic considerations |
| Q35952218 | Do statins offer therapeutic potential in inflammatory arthritis? |
| Q24804153 | Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? |
| Q51031991 | Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice. |
| Q36752124 | Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity? |
| Q33935447 | Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice |
| Q42220154 | Effect of statin therapy on vaspin levels in type 2 diabetic patients |
| Q46372426 | Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients |
| Q33738872 | Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study |
| Q37067559 | Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study |
| Q44378566 | Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease |
| Q46976978 | Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. |
| Q42060815 | Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial |
| Q36313477 | Experimental evaluation of analgesic and anti-inflammatory activity of simvastatin and atorvastatin |
| Q60665626 | Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells |
| Q53303647 | Genetic and Pharmacological Modulation of Akt1 for Improving Ovarian Graft Revascularization in a Mouse Model. |
| Q37728825 | HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size |
| Q34973446 | High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment |
| Q26774939 | How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart? |
| Q44520782 | Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits |
| Q90389973 | Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology |
| Q35637017 | If It's Not One Thing, It's Another: An Inverse Relationship of Malignancy and Atherosclerotic Disease |
| Q58197587 | Immunological aspects of atherosclerosis |
| Q40571558 | Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation |
| Q28196900 | Inflammation in atherosclerosis: causal or casual? The need for randomized trials |
| Q36597131 | Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice |
| Q33958420 | Lack of association between adiponectin levels and atherosclerosis in mice |
| Q51589940 | Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-/- mice. |
| Q37710107 | Lipid lowering and imaging protease activation in atherosclerosis |
| Q42819316 | Long‐Term Statin Therapy Affects the Severity of Chronic Gastritis |
| Q34668154 | Low level bacterial endotoxin activates two distinct signaling pathways in human peripheral blood mononuclear cells. |
| Q36733402 | Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice |
| Q38270933 | Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3 |
| Q57398888 | Modulation of adhesion molecule expression on endothelial cells: to be or not to be? |
| Q38358594 | Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells |
| Q35936423 | Molecular, cellular and functional imaging of atherothrombosis |
| Q38234426 | Most appropriate animal models to study the efficacy of statins: a systematic review. |
| Q36462055 | Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis |
| Q35551180 | Noncholesterol-Lowering Effects of Statins |
| Q35901096 | Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study |
| Q35164779 | Novel simvastatin inhalation formulation and characterisation |
| Q42245355 | Optimization of caseinate-coated simvastatin-zein nanoparticles: improved bioavailability and modified release characteristics. |
| Q46769773 | PAF-receptor antagonists, lovastatin, and the PTK inhibitor genistein inhibit H2O2 secretion by macrophages cultured on oxidized-LDL matrices |
| Q37519710 | Pharmacotherapy of coronary atherosclerosis |
| Q36342600 | Pharmacotherapy of hyperlipidemia in pediatric heart transplant recipients: current practice and future directions |
| Q34684290 | Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction |
| Q35773020 | Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease. |
| Q37486124 | Pitfalls in the assessment of murine atherosclerosis |
| Q46238735 | Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice |
| Q40055455 | Prehospital HMG Co-A reductase inhibitor use and reduced mortality in hemorrhagic shock due to trauma |
| Q54203490 | Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? |
| Q44177995 | Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice |
| Q48419319 | RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. |
| Q36243216 | Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. |
| Q46125150 | Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation |
| Q42324363 | Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein e(-/-) mice |
| Q43297706 | Simvastatin attenuates experimental small airway remodelling in rats |
| Q53587762 | Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. |
| Q38915444 | Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK. |
| Q46287146 | Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation |
| Q44485529 | Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation |
| Q34541085 | Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet |
| Q37362915 | Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model |
| Q37294495 | Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? |
| Q34986368 | Stabilization of atherosclerotic plaques: new mechanisms and clinical targets |
| Q36785461 | Statin drugs mitigate cellular inflammatory response after ST elevation myocardial infarction, but do not affect in-hospital mortality |
| Q54105644 | Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. |
| Q37098888 | Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts |
| Q64135581 | Statin therapy prior to ICU admission: protection against infection or a severity marker? |
| Q53275805 | Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis. |
| Q36549172 | Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells |
| Q34989692 | Statins and C-reactive protein: considering a novel marker of cardiovascular risk |
| Q38097749 | Statins and autoimmunity |
| Q33955458 | Statins and bones |
| Q39949859 | Statins are not associated with short-term improved aneurysm healing in a rabbit model of unruptured aneurysms. |
| Q34942903 | Statins as anti-inflammatory agents |
| Q36382202 | Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? |
| Q91584719 | Statins can suppress DC-mediated Th2 responses through the repression of OX40-ligand and CCL17 expression |
| Q36071708 | Statins induce the accumulation of regulatory T cells in atherosclerotic plaque |
| Q46623182 | Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression |
| Q42022575 | Synthesis and Characterization of a Poly(ethylene glycol)-Poly(simvastatin) Diblock Copolymer |
| Q92241365 | Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation |
| Q39277616 | The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature |
| Q28535276 | The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times |
| Q36882866 | The Treatment of Disorders of Lipid Metabolism |
| Q24684244 | The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins |
| Q45273763 | The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. |
| Q42788265 | The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice |
| Q35153749 | The lipid and non-lipid effects of statins |
| Q34742808 | The potential for novel anti-inflammatory therapies for coronary artery disease |
| Q36959612 | The role of simvastatin in the therapeutic approach of rheumatoid arthritis |
| Q34027495 | Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis |
| Q45204273 | Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. |
| Q34327988 | Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial |
| Q36025968 | Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk |
| Q39773167 | Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research |
| Q37651668 | Vascular function during prolonged progression and regression of atherosclerosis in mice |
| Q35548908 | Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice |
Search more.